Evaluating the Impact of a Tetravalent Vaccine in Populations with High-Incidence of Dengue: A Mathematical Model
|
|
- Egbert Thornton
- 5 years ago
- Views:
Transcription
1 Nonlinear Analysis and Differential Equations, Vol. 4, 216, no. 3, HIKARI Ltd, Evaluating the Impact of a Tetravalent Vaccine in Populations with High-Incidence of Dengue: A Mathematical Model Irma Pérez C., Maria E. Cardenas P., Miguel A. Enriquez G., Alejandro Juárez D. Facultad de Medicina Benemérita Universidad Autónoma de Puebla Puebla, Puebla, México Anibal Muñoz L. Facultad de Educación Grupo de Modelación Matemática en Epidemiología (GMME) Universidad del Quindío Armenia, Colombia Copyright c Irma Pérez C. et al. This article is distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract We have formulated a simulation model for different tetravalent vaccination strategies by using an integral equations system. This one interprets the dynamics of the Dengue vector-host infectious process. Keywords: Simulation model, tetravalent vaccine, host-vector, integral equations, Dengue 1 Introduction Dengue is an infectious febrile disease, of systemic viral etiology that is transmitted by Aedes sp mosquitoes. It has a variable clinical symptomatology, a little-predictive evolution, self-limited, and temporarily disabling. Dengue
2 134 Irma Pérez C. et al. presents several clinical manifestations: as fever, hemorrhagic fever, and shock syndrome. It is an arbovirus (arthropod-borne virus) with four serotypes; these ones have been grouped together using biologic, immunological, and molecular criteria, as follows: Denv-1, Denv-2, Denv-3, and Denv-4. The virus has immunological and antigenic properties that are given by structural (P, M, E) and non-structural (NS1, NS2) antigens. It is present in blood (viremia) within the first five days of the fever onset [6]. Actually, the main efforts have been done principally in the development of vaccines against Dengue. This research has focused in live attenuated vaccines, inactivated ones, and with sub-unities. The live-attenuated-vaccines have affronted several questions since the disease in the second infection may cause severe clinical signs, as: hemorrhagic fever or shock syndrome. The antibodies produced by an infection help to protect people in a new infection. However, existence of heterologous antibodies increases the infected cells by bonding with the virus (infection enhancement). The complex virusantibody binds with Fc receptors at the cell s surface to trigger severe clinical manifestations. It is highly important to have tetravalent live-attenuatedvaccines that produce antibodies for all serotypes of Dengue [1]. In the past decades it has increased the Dengue incidence around the world. The real number of cases is not documented enough and a lot of these cases are badly classified. In a recent estimation it has been reported 39 million of infections each year (this interval with 95% of certainty, 284 to 528 million), from which, 96 million (67 to 136 million) are clinically manifested [16]. People cares about this growing worldwide epidemic, that is why, an effective and safe vaccination plan necessary is. The World Health Organization (WHO) has taken the vaccines as an integral prevention and control strategy in the entire world (from 212 to 22) [19, 2, 21]. So then, the evaluation of the vaccination impact in Dengue virus for different scenarios, using mathematical models, allows us to have an improvement of the prevention strategies against this disease. In this context, we have evaluated the impact of a tetravalent vaccine in a population with high Dengue incidence in Mexico by using a host-vector-like mathematical model. With this evaluation it is possible to set valid strategies for the vaccine application. Some other models treating transmission and incidence of Dengue as func-
3 Evaluating the impact of a tetravalent vaccine in populations tion of the Temperature are reported in [5, 1, 18] and models applied to vaccination strategies in [4, 7, 9, 13, 14, 15, 17]. 2 The Model We have formulated a simulation model that plays the Dengue transmission and incidence dynamics using integral equations, with the following assumptions: Risk group (susceptible persons) until an age a. The vaccine is given to people who recently meet the age a. Prevention is given to susceptible people by means of vaccination. The vaccine is given to infected people. We have considered the infected-people recovery to one of the virus serotypes. The vaccine is 1% effective against all virus serotypes. Demography is not considered. We have considered the vector s life-cycle. We consider a biological stage that includes: eggs, larvae, and pupas. Control of the mosquito population growth. The model has the following variables: x 1 (t) average number of susceptible persons, x 2 (t) average number of infectious persons, x 3 (t) average number of immune people to all virus serotypes, x 4 (t) average number of immune people to one virus serotype, N = x 1 + x 2 + x 3 + x 4 : the total population, y 1 (t) average number of non-carrier mosquitoes, y 2 (t) average number of virus - carrier mosquitoes, M = y 1 + y 2 : is the total mosquito population, and z(t) average number of immature stages at time t, respectively. The parameters are: K(t) the charge capacity of the immature stages, ρ the constant flux of people who recently meets the age a, β h the virus transmission probability from mosquito to human, β v the virus transmission probability from people to non-carrier mosquitoes, θ the infectious people recovery rate by treatment, η : increasing flux of the adult mosquitoes population, r increasing - fraction in the number of non-carrier mosquitoes, π the adult mosquitoes natural mortality rate, ω the developing rate from pupa to adult stage, ɛ the immature stages mortality rate, φ the oviposition rate, and g the eggs fraction
4 136 Irma Pérez C. et al. that turns to female mosquito. We implement the following strategies: f : the vaccinated people fraction of age a and 1 f : the susceptible non - vaccinated people fraction of age a. j : the susceptible people fraction that are protected by vaccination, after that, 1 j : is the susceptible people fraction that are not vaccinated. σ : the infected people fraction that are vaccinated and 1 σ : the non - vaccinated infected people fraction that recovers from one of the virus serotypes. The integral equations system that interprets the infectious process is, x 1 (t) = x 1 () + (1 f)ρ x 2 (t) = x 2 () + β h (1 j) x 3 (t) = x 3 () + fρ x 4 (t) = x 4 () + (1 σ)θ N(s)ds β h (1 j) N(s)ds + σθ y 2 (s) M(s) x 1(s)ds θ y 2 (s) M(s) x 1(s)ds (1) x 2 (s)ds (2) x 2 (s)ds (3) x 2 (s)ds (4) x 2 (s) y 1 (t) = y 1 () + rηt + ω z(s)ds β v N(s) y 1(s)ds π y 1 (s)ds(5) x 2 (s) t y 2 (t) = y 2 () + (1 r)ηt + β v N(s) y 1(s)ds π y 2 (s)ds (6) ( z(t) = z() + gφ (y 1 (s) + y 2 (s)) 1 z(s) ) ds ɛ z(s)ds (7) K N(t) = N() + ρ M(t) = M() + ηt π N(s)ds (8) M(s)ds + ω z(s)ds (9)
5 Evaluating the impact of a tetravalent vaccine in populations x 4 (t) fρn (1 σ)θx 2 (1 f)ρn x 1 (t) β h (1 j) y 2 (t) M(t) x 1(t) x 2 (t) σθx 2 (t) x 3 (t) rη y 1 (t) β v x 2 (t) N(t) y 1(t) y 2 (t) (1 r)η ωz(t) πy 1 (t) πy 2 (t) Ω z(t) ɛz(t) ( Fig 1. Flux diagram of the dynamics, with Ω = gφ(y 1 (t) + y 2 (t)) 1 z(t) k where, ρ, θ, ω, ɛ, η, φ, K, π >, < β h, β v, σ, f, r, j < 1 and initial conditions x 1 () = x 1, x 2 () = x 2, x 3 () = x 3, x 4 () = x 4, y 1 () = y 1, y 2 () = y 2, z() = z. ). 3 Results and conclusions We carry out all simulations with the Maple software, using literature values for the parameters and some other hypothetical ones. π =.1, η = 1, g =.6, β h =.75, β v =.75, φ = 8, K = 3, θ =.8, ɛ =.96, ω =.94, ρ =.1 and r =.1. Figures 1, 2, and 3 correspond to the following strategies E : f =, j = and σ = (straight line) E 1 : f =, j =.3 and σ =.4 (dashed line) E 2 : f =.4, j = and σ =.4 (dotted line)
6 138 Irma Pérez C. et al. E 3 : f =.4, j =.3 and σ = (dash-dot-dash line). Figure 1: The infected people behavior (x 2 (t)) for each strategy. Comparing the parameters (x 2 (t), x 3 (t), x 4 (t)) and (y 2 (t)) with the ones obtained without vaccination, it is possible to observe that the infected people number in strategy E 3 is higher than that the ones obtained with strategies (E 1, E 2 ) and without vaccination (E ), see Figure 1. Taking into account that this strategy (E 3 ) includes a 4% of vaccination to 9-years-old susceptible population and a 3% of vaccination applied to people as prevention. The virus-carrier mosquito behavior remains almost unchanged even after application of all treated strategies (E, E 1, E 2 ) and (E 3 ), as seen in Figure 2. The immune-people behavior to all virus serotypes shows that there exists a higher average number of immune people to all virus serotypes with strategy E 2 (upper part of Figure 3). Also, in second place it is found the strategy E 3 and the last one, with values under 35, strategy E 1. In Figure 3 (bottom part) is showed the immune people behavior to only one virus serotype, it is clear that the highest values are obtained when there is not vaccine application. We have determined the key parameters in a mathematical model that are
7 Evaluating the impact of a tetravalent vaccine in populations Figure 2: The virus carrier mosquito behavior (y 2 (t)) for each strategy. related with the effectiveness of a tetravalent vaccine against dengue. It has been used three different vaccination strategies in a 9 to 23 years old population from an endemic zone in México. Our results have in some sense an agreement with other studies applied to populations with this similar issue. As example, a study realized in 5 countries of Latin America, where, it was evaluated the effectiveness of a tetravalent vaccine (CYD-TDV) in a population of 2,869 children (from 9 to 16 years old). This analysis consist of a phase III essay, the obtained results showed an efficacy of 6.8% after three vaccine shots. Also, in this study has been found a high efficacy in seropositive children to one of the four virus serotypes [2, 3, 8, 11, 12] Other study realized in 5 Asian countries, where it was applied a phase-iii essay in 1,275 healthy children (from 12 to 14 years old). These children have received three doses (, 6, and 12 months) of a live attenuated virus recombinant vaccine (CYD-TDV). Results show that the symptomatology, fever by Dengue, and some other adverse effects were minimum compared with the control group, showing a 56.5% of vaccine effectiveness. Finally, in other phase-ii essay in a children cohort in Brasil (from 9 to 16 years old), the obtained results with the same vaccine (CYD-TDV) show that it was also effective for all four virus serotypes, being well admitted by children. Reinforcing the findings for phase-i and phase-ii vaccines [4].
8 14 Irma Pérez C. et al. Figure 3: Upper part, immune people behavior to all virus serotypes (x 3 (t)), and bottom part, immune people behavior to only one virus serotype in each strategy (x 4 (t)). Acknowledgements. AML thanks to: Facultad de Medicina de la Benemérita Universidad Autónoma de Puebla, México; Al grupo de Modelación
9 Evaluating the impact of a tetravalent vaccine in populations Matemática en Epidemiología (GMME), Facultad de Educación de la Universidad de Quindío, Colombia. References [1] B. M. Zambrano, Estado actual de las vacunas contra el Dengue. Perspectivas, Rev. Biomed, 21 (21), no. 3, [2] D. Garde, Sanofi s 1.5 B dengue vaccine shows Phase III promise, but questions linger, Fierce Biotech, 214. [3] G. H. Dayan, et al., Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil, American Journal of Tropical Medicine and Hygiene, 89 (213), no. 6, [4] H. Tasman, A. K. Supriatna, N. Nuraini, E. Soewono, A dengue vaccination model for immigrants in a two-age-class population, International Journal of Mathematics and Mathematical Sciences, 212 (212), article ID , [5] J. Liu-Helmersson, H. Stenlund, A. Wilder-Smith, J. Rocklöv, Vectorial Capacity of Aedes aegypti: Effects of Temperature and Implications for Global Dengue Epidemic Potential, PLOS ONE, 9 (214), no. 3, e [6] J. R. Barba, Dengue. Problema que preocupa y ocupa a la salud pública, Rev. Latinoam. Patol. Clin. Med. Lab., 61 (214), no. 2, [7] L. Billings, A. Fiorillo, I. B. Schwartz, Vaccinations in disease models with antibody-dependent emhancement, Mathematical Biosciences, 211 (28), [8] L. Coudeville, et al., Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies, Vaccine, (215). [9] L. Villar, et al., Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America, New England Journal of Medicine, 372 (215), [1] L. M. Hartley, C. A. Donelly and G. P. Garnett, The seasonal pattern of dengue in endemic areas: mathematical models of mechanisms, J. Transactions of the Royal Society of Tropical Medicine and Hygiene, 96 (22), no. 4,
10 142 Irma Pérez C. et al. [11] M. R. Capeding, et al., Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial, The Lancet, 384 (214), no. 9951, [12] O. J. Brady, P. W. Gething, et al., Refining the global spatial limits of dengue virus transmission by evidence-based consensus, PLoS Negl Trop Dis., 6 (212), e [13] P. Abhishek, Modeling Dengue Transmission and Vaccination, Diss., Graduate School of Clemson University, 214. [14] P. Porwal, V. H. Badshah, A study of dengue disease model with vaccination strategy, International Journal of Engineering Research and General Science, 3 (215), [15] S. Aureliano Carvalho, S. O. da Silva, I. da Cunha Charret, Mathematical modeling of dengue epidemic: Control methods and vaccination satrategies, Preprint submitted to Applied Mathematics and Computation, (215). [16] S. Bhatt, P. W. Gething, et al., The global distribution and burden of dengue, Nature, 496 (213), [17] S. Mahalingam, B. L. Herring, B. S. Halstead, Call to action for dengue vaccine failure, Emerg. Infect. Dis., 19 (213), [18] S. Polwiang, The Seasonal Reproduction Number of Dengue Fever: Impacts of Climate to Transmission, PeerJ, 3 (215), e [19] Simposio regional del dengue, Rio de Janeiro Brasil, Nov [2] WHO report: Global Strategy for Dengue Prevention and Control, [21] WHO-VMI Dengue Vaccine Modeling Group, Assessing the potential of a candidate dengue vaccine with mathematical modeling, PLoS Neglected Tropical Diseases, 6 (212), no. 3, e Received: December 15, 215; Published: February 11, 216
A Simulation Model Including Vaccination and Seasonality for Influenza A-H1N1 Virus
Applied Mathematical Sciences, Vol. 10, 2016, no. 26, 1269-1276 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/ams.2016.511694 A Simulation Model Including Vaccination and Seasonality for Influenza
More informationHow Relevant is the Asymptomatic Population in Dengue Transmission?
Applied Mathematical Sciences, Vol. 12, 2018, no. 32, 1699-1708 HIKARI Ltd, www.m-hikari.com https://doi.org/10.12988/ams.2018.810150 How Relevant is the Asymptomatic Population in Dengue Transmission?
More informationAnalysis of a Mathematical Model for Dengue - Chikungunya
Applied Mathematical Sciences, Vol. 11, 217, no. 59, 2933-294 HIKARI Ltd, www.m-hikari.com https://doi.org/1.12988/ams.217.7135 Analysis of a Mathematical Model for Dengue - Chikungunya Oscar A. Manrique
More informationNumerical Analysis of the Prevention with Vaccination Against Zika Virus (ZIKV)
Contemporary Engineering Sciences, Vol. 12, 2019, no. 1, 33-40 HIKARI Ltd, www.m-hikari.com https://doi.org/10.12988/ces.2019.913 Numerical Analysis of the Prevention with Vaccination Against Zika Virus
More informationImpact of the Latent State in the R 0 and the Dengue Incidence
Applied Mathematical Sciences, Vol. 12, 2018, no. 32, 1709-1718 HIKARI Ltd, www.m-hikari.com https://doi.org/10.12988/ams.2018.810154 Impact of the Latent State in the R 0 and the Dengue Incidence Angie
More informationSimulating the Effect of Aedes aegypti by the Acquired Resistance to Chemicals
Applied Mathematical Sciences, Vol. 12, 2018, no. 29, 1433-1440 HIKARI Ltd, www.m-hikari.com https://doi.org/10.12988/ams.2018.810155 Simulating the Effect of Aedes aegypti by the Acquired Resistance to
More informationThe Effectiveness of Dengue Vaccine and Vector Control: Model Study
KMUTNB Int J Appl Sci Technol, Vol. 11, No. 3, pp. 225 232, 218 Research Article The Effectiveness of Dengue Vaccine and Vector Control: Model Study Sittisede Polwiang* Department of Mathematics, Faculty
More informationUpdated Questions and Answers related to the dengue vaccine Dengvaxia and its use
WHO Secretariat Updated Questions and Answers related to the dengue vaccine Dengvaxia and its use Published 22 December 2017 This document takes into account new and unpublished data that were communicated
More informationAuchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1
EPIDEMIOLOGY OF DENGUE AT THAMMASAT UNIVERSITY HOSPITAL DURING 2006-2015 Auchara Tangsathapornpong 1, Churairat Puriburt 2 and Pornumpa Bunjoungmanee 1 1 Department of Pediatrics, Faculty of Medicine,
More informationDengue: The next vaccine preventable disease? Prof John McBride James Cook University
Dengue: The next vaccine preventable disease? Prof John McBride James Cook University Dengue viruses A flavivirus ~11kb genome, ~50nm diameter, lipid envelope. Gene order 5 C-prM-E-NS1 Four serotypes (1-4)
More informationMODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America
MODULE 5 Dengue Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America Symptoms of Dengue Fever Dengue: Skin rashes DHF manifestations Hemorrhages Thrombocytopenia
More informationLecture 9: Stochastic models for arboviruses. Ira Longini
Lecture 9: Stochastic models for arboviruses Ira Longini The Ross-MacDonald Model for Vector Bourne Infectious Diseases Sir Ronald Ross (1857-1932) Liverpool School of Tropical Medicine The 2 nd Nobel
More informationDOI: /ICJ (Dengue fever) [2] (Aedes aegypti) (Aedes albopictus) (Dengue. (Flavivirus) 50 nm. ssrna) (capsid, C) ( ) (membrane, prm/m)
210 DOI: 10.6526/ICJ.2016.504 T (Dengue fever) [1] 128 39 [2] 4 5 21,000 [3] 3 1981 1987 1995 2014 [4] 2015 ( ) (Aedes aegypti) (Aedes albopictus) (Dengue virus) (Flaviviridae) (Flavivirus) 50 nm 11 kb
More informationResults of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine
Results of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine Maria Rosario Z. Capeding, MD Research Institute for Tropical Medicine Philippines From
More informationModeling the HIV Transmission with Reinfection
Applied Mathematical Sciences, Vol. 9, 2015, no. 87, 4323-4330 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/ams.2015.52174 Modeling the HIV Transmission with Reinfection Juan C. Castillo Paz,
More informationMATHEMATICAL STUDY OF BITING RATES OF MOSQUITOES IN TRANSMISSION OF DENGUE DISEASE
ORIGINAL RESEARCH ARTICLE OPEN ACCESS MATHEMATICAL STUDY OF BITING RATES OF MOSQUITOES IN TRANSMISSION OF DENGUE DISEASE *G. R. Phaijoo, D. B. Gurung Department of Natural Sciences (Mathematics), School
More informationModelling the risk of dengue for tourists in Rio de Janeiro, during. Janeiro, during the FIFA confederation cup in Brazil 2013
Modelling the risk of dengue for tourists in Rio de Janeiro, during the FIFA confederation cup in Brazil 2013 Raphael Ximenes, Eduardo Massad University of São Paulo November, 2013 Mathematical modeling
More informationStructured models for dengue epidemiology
Structured models for dengue epidemiology submitted by Hannah Woodall for the degree of Doctor of Philosophy of the University of Bath Department of Mathematical Sciences September 24 COPYRIGHT Attention
More informationDengue is one of the most rapidly spreading mosquito-borne viral diseases in the world and
Abstract Dengue is one of the most rapidly spreading mosquito-borne viral diseases in the world and inflicts significant health, economic and social burden on populations. Various mathematical models have
More informationDengue vaccine: WHO position paper July 2016
Dengue vaccine: WHO position paper July 2016 References with abstracts cited in the position paper in the order of appearance. World Health Organization. Global Strategy for dengue prevention and control,
More informationModeling results / SDF: Routine vaccination strategy Introduction catch-up strategy
Modeling results / SDF: Routine vaccination strategy Introduction catch-up strategy Ira Longini, Diana Rojas, Tom Hladish CSQUID, University of Florida, Gainesville, FL Betz Halloran, Dennis Chao Fred
More informationOverview of a neglected infectious disease: dengue
Overview of a neglected infectious disease: dengue Outline Current epidemiological trends Mechanisms underlying dengue transmission Dengue control Overview of recent modeling efforts Drivers of serotype
More informationDengue Update. Actualització sobre dengue
Leading research at: Dengue Update Click to edit Master subtitle style Actualització sobre dengue Ned Hayes, MD Dengue Leading research at: Caused by infection with one of 4 viruses DEN-1, DEN-2, DEN-3,
More informationLEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS
FACT SHEET LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS A GLOBAL PUBLIC HEALTH CHALLENGE Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat
More informationMathematical Modelling the Spread of Zika and Microcephaly in Brazil.
Proceedings of the 17th International Conference on Computational and Mathematical Methods in Science and Engineering, CMMSE 2017 4 8 July, 2017. Mathematical Modelling the Spread of Zika and Microcephaly
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More informationSummary of Key Points WHO Position Paper on Dengue Vaccine, September 2018
Summary of Key Points WHO Position Paper on Dengue Vaccine, September 2018 For more information on the WHO Dengue position paper, please visit the WHO website: www.who.int/immunization/documents/positionpapers
More informationDengue Virus-Danger from Deadly Little Dragon
Molecular Medicine Dengue Virus-Danger from Deadly Little Dragon Dr.G.MATHAN Assistant Professor Department of Biomedical Science Bharathidasan University Tiruchirappalli, Tamil Nadu Vector (A carrier)
More informationDengue Vaccine. Irani Ratnam The Royal Melbourne Hospital & Peter Doherty Institute
Dengue Vaccine Irani Ratnam The Royal Melbourne Hospital & Peter Doherty Institute No Conflicts of interest Dengue Dengue virus (DENV), a member of the genus Flavivirus Vector-borne disease transmitted
More informationProblem for the Optimal Control of Cigarette Addiction
Contemporary Engineering Sciences, Vol. 12, 2019, no. 1, 41-49 HIKARI Ltd, www.m-hikari.com https://doi.org/10.12988/ces.2019.914 Problem for the Optimal Control of Cigarette Addiction Anibal Muñoz L.,
More informationCYD-TDV Dengvaxia clinical update
Chris Nelson Sanofi Pasteur CYD-TDV Dengvaxia clinical update "Arboviruses: A Global Public Health Threat" 20-22 June 2018 Les Pensières Center for Global Health, Veyrier-du-Lac (France) JUNE 2018 1 The
More informationMathematical Models for the Control of Infectious Diseases With Vaccines
Mathematical Models for the Control of Infectious Diseases With Vaccines Ira Longini Department of Biostatistics and Center for Statistical and Quantitative Infectious Diseases (CSQUID), University of
More informationProposal for a Workshop
Proposal for a Workshop Pre-vaccination screening for the use of dengue vaccines with differential performance dependent on serostatus: rapid diagnostic tests and implementation strategies Background:
More informationSymptomatic Dengue in Children in 10 Asian and Latin American Countries
The new england journal of medicine Original Article Symptomatic Dengue in Children in 10 Asian and Latin American Countries Maïna L Azou, M.Sc., Annick Moureau, M.Sc., Elsa Sarti, Ph.D., Joshua Nealon,
More informationDengue and Zika vaccine development
Dengue and Zika vaccine development Carolyn E. Clark, PhD, MPH Scientist, Infection Control and Environmental Health Norwegian Institute of Public Health Kurs i import- og reisemedisin for helsepersonell
More informationNew epidemiological perspectives coming from dengue vaccine clinical trials. João Bosco Siqueira Jr Federal University of Goias - Brazil
New epidemiological perspectives coming from dengue vaccine clinical trials João Bosco Siqueira Jr Federal University of Goias - Brazil Dengue Key Facts The global incidence of dengue has grown dramatically
More informationA. Study Purpose and Rationale
IRB Proposal/CRC Rotation Sabrina J Gard, MD MPH Internal Medicine, PGY 1 5 May 2014 A. Study Purpose and Rationale Dengue is the most prevalent arthropod-transmitted virus, with conservative estimates
More informationDengue Vaccine (CYD-TDV Dengvaxia )
Dengue Vaccine (CYD-TDV Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Lee Kong Chian School of Medicine, Singapore Director, Partnership for Dengue Control, Fondation
More informationMathematics Model Development Deployment of Dengue Fever Diseases by Involve Human and Vectors Exposed Components
Volume-8, Issue-4, August 2018 International Journal of Engineering and Management Research Page Number: 46-53 DOI: doi.org/10.31033/ijemr.8.4.5 Mathematics Model Development Deployment of Dengue Fever
More informationDENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo
DENGUE AND BLOOD SAFETY Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo Dengue virus Arbovirus (arthropod-borne virus) virus transmitted by mosquitoes:
More informationModeling Pulmonary Tuberculosis for Optimal Control Including Prevention
British Journal of Mathematics & Computer Science 21(6): 1-8, 2017; Article no.bjmcs.30381 ISSN: 2231-0851 SCIENCEDOMAIN international www.sciencedomain.org Modeling Pulmonary Tuberculosis for Optimal
More informationsp second generation tetravalent dengue vaccine
sp second generation tetravalent dengue vaccine CYD23 Study Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 1 Years in Thailand Alain Bouckenooghe, MD, MPH, DTM&H Clinical R&D, Head
More informationDengue Vaccine Butantan Institute. DCVMN, Bangkok, 2015
Dengue Vaccine Butantan Institute DCVMN, Bangkok, 2015 GENOME Dengue Viruses Dengue is a mosquito-borne RNA virus with 4 distinct serotypes: 1,2,3,and 4 3 structural proteins: C, prm, and E E protein is
More informationDengue Vaccines: current status of development
Dengue Vaccines: current status of development ISID-NTD 2011 International Meeting, Boston Satellite Symposium on Dengue Control, 10 July 2011 Pem Namgyal WHO/IVB/IVR 1 Presentation Outline! Summary of
More informationThe correlation between temperature and humidity with the population density of Aedes aegypti as dengue fever s vector
IOP Conference Series: Earth and Environmental Science PAPER OPEN ACCESS The correlation between temperature and humidity with the population density of Aedes aegypti as dengue fever s vector To cite this
More informationDependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine
Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine Yang Yang, PhD 1, Ya Meng, PhD 1, M. Elizabeth Halloran, DSc, MD 2,3, Ira M. Longini, Jr., PhD 1 August
More informationEdwin J. Asturias Associate Director
Edwin J. Asturias Associate Director Center for Global Health Associate Professor of Pediatrics and Epidemiology Effectiveness Dengue Vaccine Washington DC, June 2014 UNIVERSITY OF COLORADO COLORADO STATE
More informationMaking Dengue a Vaccine Preventable Disease
Making Dengue a Vaccine Preventable Disease Harold S. Margolis, MD, FAAP Joint International Tropical Medicine Meeting (JITMM) Bangkok, Thailand October 13, 2008 Dengue Vaccines Where are We Today? No
More informationImmune protection against dengue infection. Vaccine performance
Immune protection against dengue infection. Vaccine performance SCOTT B HALSTEAD MD Department of Preventive Medicine Uniformed Services University of the Health Sciences TOPICS Current dengue vaccines:
More informationAssessment of dengue vaccine effectiveness and impact for different rollout strategies
Assessment of dengue vaccine effectiveness and impact for different rollout strategies Diana P. Rojas and Ira Longini Center for Inference and Dynamics of Infectious Diseases Emerging Pathogens Institute
More informationPrevention of arboviral diseases. Willem Takken & Sander Koenraadt Laboratory of Entomology Wageningen University and Research
Prevention of arboviral diseases Willem Takken & Sander Koenraadt Laboratory of Entomology Wageningen University and Research Brussel, 25 januari 2018 Arbivoral diseases affecting humans Mosquito borne:
More informationA Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone
A Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone First Regional Dengue Symposium, Rio de Janeiro, Brazil Nov 3-4 2015 Pedro Garbes, MD. Regional Medical Director, Latin America.
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(6):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 06 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.706.128
More informationSAGE deliberations on CYD-TDV ( Dengvaxia )
SAGE deliberations on CYD-TDV ( Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Scientific Coordinator ZIkaPLAN Director, Partnership for Dengue Control, Fondation
More informationUsa Thisyakorn and Chule Thisyakorn
CHILDHOOD DENGUE DISEASES: A TWENTY YEARS PROSPECTIVE STUDY Usa Thisyakorn and Chule Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. Dengue
More informationThe importance of schools and other non-household sites for dengue entomological risk
The importance of schools and other non-household sites for dengue entomological risk Audrey Lenhart, MPH, PhD US Centers for Disease Control and Prevention (CDC) Liverpool School of Tropical Medicine
More informationDuane J. Gubler, ScD Professor and Founding Director, Signature Research Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
Duane J. Gubler, ScD Professor and Founding Director, Signature Research Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore AGENDA Other arboviruses with the potential for urban
More informationArboviruses: A Global Public Health Threat
Arboviruses: A Global Public Health Threat Les Pensières Center for Global Health Veyrier-du-Lac - France 20-22 June 2018 Steering Committee: Duane Gubler Mauricio Lacerda Nogueira Jacques Louis Christopher
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationSeroprevalence and Recent Trends of Dengue in a Rural Area in South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 1 (2017) pp. 36-41 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.601.005
More informationModeling the impact of vertical transmission in vectors on the dynamics of dengue fever
ISSN 1 746-7233, England, UK World Journal of Modelling and Simulation Vol. 13 (2017) No. 3, pp. 219-227 Modeling the impact of vertical transmission in vectors on the dynamics of dengue fever Nkuba Nyerere
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationON THE DYNAMICS OF SIMULTANEOUS SPREADING OF TWO-STRAIN DENGUE SEROTYPES
ON THE DYNAMICS OF SIMULTANEOUS SPREADING OF TWO-STRAIN DENGUE SEROTYPES Leandro J. ieira da Maia, Kátya Regina de Freitas, Reginaldo A. Zara Universidade Estadual do Oeste do Paraná - Unioeste Centro
More informationGlobal Perspectives on Dengue Research
By Scott B. Halstead Adjunct Professor, Department of Preventive Medicine, Uniformed Services, University of the Health Sciences, Bethesda, MD, USA Abstract Dengue viruses infect nearly 100 million human
More informationDengue Conference, Mandurai, India, July What role should mathematical models & transgenic mosquitoes play in dengue control programs in India?
Dengue Conference, Mandurai, India, July 2013 What role should mathematical models & transgenic mosquitoes play in dengue control programs in India? John M. Marshall Department of Infectious Disease Epidemiology,
More informationSUPPLEMENTARY INFORMATION
!""#$%&'()*(+$,-./$!"#$%&"#'($)'(*'+$,-$.'#/.0$!12$,134-0$ 5+(6)+7#8#')$9:$;+
More informationAnalysis of the basic reproduction number from the initial growth phase of the outbreak in diseases caused by vectors
Analysis of the basic reproduction number from the initial growth phase of the outbreak in diseases caused by vectors University of São Paulo Medicine School rosangelasanches@usp.br November,2013 Introduction
More informationVaccine prevention for existing and emerging viral threats
Vaccine prevention for existing and emerging viral threats Viruses in May Blue Mountains 18 May 2018 www.ncirs.edu.au https://www.apprise.org.au/ Prof Kristine Macartney Director, NCIRS www.ncirs.usyd.edu.au
More informationAnnual Epidemiological Report
August 2018 Annual Epidemiological Report 1 Vectorborne disease in Ireland, 2017 Key Facts 2017: 10 cases of dengue were notified, corresponding to a crude incidence rate (CIR) of 0.2 per 100,000 population
More informationA Stochastic Spatial Model of the Spread of Dengue Hemorrhagic Fever
Volume-7, Issue-5, September-October 2017 International Journal of Engineering and Management Research Page Number: 98-104 A Stochastic Spatial Model of the Spread of Dengue Hemorrhagic Fever A. R. Nuha
More informationAn integrated approach to understanding knowledge, attitudes and practices surrounding dengue in emergent and endemic areas
An integrated approach to understanding knowledge, attitudes and practices surrounding dengue in emergent and endemic areas Mary Hayden National Center for Atmospheric Research Boulder, Colorado, USA 5
More informationDynamics and Control of Infectious Diseases
Dynamics and Control of Infectious Diseases Alexander Glaser WWS556d Princeton University April 9, 2007 Revision 3 1 Definitions Infectious Disease Disease caused by invasion of the body by an agent About
More informationMaria Eugenia Toledo Institute of Tropical Medicine Pedro Kouri, Cuba
Maria Eugenia Toledo Institute of Tropical Medicine Pedro Kouri, Cuba The most important arthropod borne viral disease No vaccine DENGUE No curative treatment Vector-control strategies failed to counter
More informationTowards Dengue Vaccine Introduction:! Report of the Asia-Pacific Dengue Prevention Board Meeting
Towards Dengue Vaccine Introduction:! Report of the Asia-Pacific Dengue Prevention Board Meeting Sri Rezeki S Hadinegoro Department of Child Health Medical Faculty University of Indonesia Lay out Introduction
More informationA Critical Protection Level Derived from Dengue Infection Mathematical Model Considering Asymptomatic and Symptomatic Classes
Journal of Physics: Conference Series A Critical Protection Level Derived from Dengue Infection Mathematical Model Considering Asymptomatic and Symptomatic Classes To cite this article: N Anggriani et
More informationDengue Vaccines: Herd Immunity Considerations
1/33 Dengue Vaccines: Herd Immunity Considerations Derek Cummings Johns Hopkins Bloomberg School of Public Health Fondation Merieux, October 27, 2010 2/33 Outline 1 2 3 Immune enhancement of transmission
More informationClinical Profile of the Dengue Infection in Children
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 3 Ver.7 March. (18), PP 01-05 www.iosrjournals.org Clinical Profile of the Dengue Infection
More informationDengue Vaccines: Status and Future
Dengue Vaccines: Status and Future In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 22 Jun 2018 Outline Tetravalent vaccination strategy
More informationTAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT. RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit
TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public
More informationEPIDEMIOLOGY AND TRANSMISSION DYNAMICS OF ARBOVIRUS IN LATIN AMERICA
EPIDEMIOLOGY AND TRANSMISSION DYNAMICS OF ARBOVIRUS IN LATIN AMERICA By DIANA P. ROJAS ALVAREZ A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE
More informationPEDIATRIC INFECTIOUS DISEASE SOCIETY OF THE PHILIPPINES, INC.
RESPONSE FROM THE PEDIATRIC INFECTIOUS DISEASE SOCIETY OF THE PHILIPPPINES REGARDING CURRENT ISSUES ON THE USE OF THE DENGUE VACCINE 12 December 2017 In December 2015, the Philippines licensed the first
More informationDownloaded from:
Maier, SB; Huang, X; Massad, ; Amaku, M; Burattini, MN; Greenhalgh, D (2017) Analysis of the Optimal Vaccination Age for Dengue in Brazil with a Tetravalent Dengue Vaccine. Mathematical biosciences. ISSN
More informationMosquito-borne virus prevention and control: a global perspective
Mosquito-borne virus prevention and control: a global perspective Chikungunya 2017, Sapienza Universita di Roma 10 November 2017 Erika Garcia Mathematical Epidemiologist World Health Organization Geneva,
More informationFact sheet. Yellow fever
Fact sheet Key facts is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow in the name refers to the jaundice that affects some patients. Up to 50% of severely affected
More informationLyme Disease: A Mathematical Approach
July 21, 2015 Overview Biology of Lyme Disease 1 Biology of Lyme Disease Borrelia burgdoferi Ixodes scapularis Hosts 2 3 Age-Structured Tick Class Model 4 Age-Structured Tick Class & Seasonality Model
More informationOutbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016
Outbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016 Overview History Distribution Modes of Transmission Symptoms Some Causal
More informationModeling the Impact of Screening and Treatment on the Dynamics of Typhoid Fever
ISSN 1 746-7233, England, UK World Journal of Modelling and Simulation Vol. 14 (2018) No. 4, pp. 298-306 Modeling the Impact of Screening and Treatment on the Dynamics of Typhoid Fever Nkuba Nyerere 1
More informationBACKGROUND PAPER ON DENGUE VACCINES
BACKGROUND PAPER ON DENGUE VACCINES REVISION TO THE BACKGROUND PAPER FROM 17 MARCH 2016 PREPARED BY THE SAGE WORKING GROUP ON DENGUE VACCINES AND WHO SECRETARIAT 18 APRIL 2018 1 TABLE OF CONTENTS 1. Executive
More informationEvaluating the promise of a transmissible vaccine. Scott L. Nuismer
Evaluating the promise of a transmissible vaccine Scott L. Nuismer Effective vaccines exist for 24 infectious diseases of humans Vaccines have had amazing successes Eradicated smallpox Driven polio to
More informationMODELLING THE SPREAD OF PNEUMONIA IN THE PHILIPPINES USING SUSCEPTIBLE-INFECTED-RECOVERED (SIR) MODEL WITH DEMOGRAPHIC CHANGES
MODELLING THE SPREAD OF PNEUMONIA IN THE PHILIPPINES USING SUSCEPTIBLE-INFECTED-RECOVERED (SIR) MODEL WITH DEMOGRAPHIC CHANGES Bill William M. Soliman 1, Aldous Cesar F. Bueno 2 1, 2 Philippine Science
More information388 Biomed Environ Sci, 2015; 28(5):
388 Biomed Environ Sci, 2015; 28(5): 388-395 Policy Forum Frequency, Duration and Intensity of Dengue Fever Epidemic Risk in Townships in Pearl River Delta and Yunnan in China, 2013 * CHEN Qian Qian &,
More informationCLIMATE SERVICES FOR HEALTH
DRAFT FOR DISCUSSION CLIMATE SERVICES FOR HEALTH Improving public health decision-making in a new climate CASE STUDIES INTEGRATED SURVEILLANCE Enabling Environment Capacity Building Research Product &
More informationDengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล
Dengue vaccine โดย ศ. พญ. ก ลก ญญา โชคไพบ ลย ก จ ภาคว ชาก มารเวชศาสตร คณะแพทยศาสตร ศ ร ราชพยาบาล SANOFI PASTEUR S DENGUE VACCINE*: THE MOST CLINICALLY ADVANCED DENGUE VACCINE CANDIDATE There are 4 genetic
More informationMATHEMATICAL MODEL OF LYME DISEASE CAUSED BY THE BACTERIUM BORRELIA BURGDORFERRI
Wednesday, 25th, 10:30 MATHEMATICAL MODEL OF LYME DISEASE CAUSED BY THE BACTERIUM BORRELIA BURGDORFERRI Antoni Leon Dawidowicz Antoni.Leon.Dawidowicz@im.uj.edu.pl Faculty of Mathematics and Computer Science,
More informationDengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO
Dengue Virus Member of the genus Flavivirus Transmitted by the Aedes mosquito; mosquito => human cycle 4 serotypes: DENV1, 2, 3, and 4 Homotypic immunity is long lasting Heterotypic immunity is short lived
More informationModelling interventions during a dengue outbreak
Epidemiol. Infect. (214), 142, 545 561. Cambridge University Press 213 doi:1.117/s95268813131 Modelling interventions during a dengue outbreak D.H.BARMAK,C.O.DORSO,M.OTERO* AND H. G. SOLARI Departamento
More informationEPIDEMIOLOGICAL STUDIES
EPIDEMIOLOGICAL STUDIES EPIDEMIOLOGIC STUDIES EPIDEMIOLOGIC STUDIES 8 Clinical Trial sites in Brasil (NICHD) Transfusion recipient study (NHLBI) Prospective study in Brasil (Yale) Natural history population
More informationThe Potential Impacts of 21st Century Climatic and Population Changes on Human Exposure to the Virus Vector Mosquito Aedes aegypti
08 February 2016 The Potential Impacts of 21st Century Climatic and Population Changes on Human Exposure to the Virus Vector Mosquito Aedes aegypti A.J. Monaghan 1, K.M. Sampson 1, D.F. Steinhoff 1, K.C.
More informationTraining in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure
Training in Infectious Diseases Modeling A reflection on vaccination as a disease control measure -Example of Rotavirus disease- Participant s Guide Adapted by Nathalie Elomeiri; Camelia Savulescu; Fernando
More informationExercises on SIR Epidemic Modelling
Exercises on SIR Epidemic Modelling 1 Epidemic model (from Wikipedia) An epidemic model is a simplified means of describing the transmission of communicable disease through individuals. The modeling of
More information